Wednesday, 23rd of August 2017 |
A randomized synbiotic trial to prevent sepsis among infants in rural India
Panigrahi P1,2, Parida S3, Nanda NC4, Satpathy R5, Pradhan L6, Chandel DS7, Baccaglini L1, Mohapatra A5, Mohapatra SS5, Misra PR5, Chaudhry R8, Chen HH9, Johnson JA10, Morris JG10, Paneth N11, Gewolb IH12.
1
Department of Epidemiology, Center for Global Health and Development, College of Public Health, University of Nebraska Medical Center, Nebraska, USA.
2
Department of Pediatrics, Center for Global Health and Development, College of Public Health, University of Nebraska Medical Center, Nebraska, USA.
3
Department of Pediatrics, SCB Medical College, Cuttack, Odisha, India.
4
Department of Pediatrics, Ispat General Hospital, Rourkela, Odisha, India.
5
Asian Institute of Public Health, Bhubaneswar, Odisha, India.
6
Department of Pediatrics, Capital Hospital, Bhubaneswar, Odisha, India.
7
Department of Environmental, Agricultural &Occupational Health, Center for Global Health and Development, College of Public Health, University of Nebraska Medical Center, Omaha, Nebraska, USA.
8
Department of Microbiology, All India Institute of Medical Sciences, New Delhi, India.
9
Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
10
Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.
11
Departments of Epidemiology, Pediatrics &Human Development, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA.
12
Division of Neonatology, College of Human Medicine, Michigan State University, East Lansing, Michigan, USA.
Abstract
Sepsis in early infancy results in one million annual deaths worldwide, most of them in developing countries. No efficient means of prevention is currently available. Here we report on a randomized, double-blind, placebo-controlled trial of an oral synbiotic preparation (Lactobacillus plantarum plus fructooligosaccharide) in rural Indian newborns. We enrolled 4,556 infants that were at least 2,000 g at birth, at least 35 weeks of gestation, and with no signs of sepsis or other morbidity, and monitored them for 60 days. We show a significant reduction in the primary outcome (combination of sepsis and death) in the treatment arm (risk ratio 0.60, 95% confidence interval 0.48-0.74), with few deaths (4 placebo, 6 synbiotic). Significant reductions were also observed for culture-positive and culture-negative sepsis and lower respiratory tract infections. These findings suggest that a large proportion of neonatal sepsis in developing countries could be effectively prevented using a synbiotic containing L. plantarum ATCC-202195.
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
40954823 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |